- MarketWatch•2 days ago
Catabasis Pharmaceuticals Inc. shares surged 17.1% in pre-market trade Thursday after the company released positive early-stage clinical trial results for its Duchenne muscular dystrophy drug. The drug, ...
- 24/7 Wall St.•2 days ago
A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
- Motley Fool•3 days ago
The potential for rapid revenue growth at Exact Sciences, Kite Pharma, Illumina, GW Pharma, and Sarepta Therapeutics could make them top stocks to buy this year.
SRPT : Summary for Sarepta Therapeutics, Inc. - Yahoo Finance
Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||32.80 x 600|
|Ask||32.85 x 100|
|Day's Range||32.45 - 34.67|
|52 Week Range||8.00 - 63.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.77|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|